Clinical Trial Update: Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for tebentafusp in molecularly relapsed melanoma shows an active but not recruiting study targeting both cutaneous and uveal melan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Uveal Melanoma

Drugs mentioned

• Tebentafusp (tebentafusp)

Snippet

Sponsor: University of Oxford | Conditions: Melanoma (Skin), Melanoma, Uveal | Phase 2 | Status: ACTIVE_NOT_RECRUITING